Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand Key Takeaways: Ascletis Pharma has shifted to weight…
1672.HK
Recent Articles
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
Innovent Bio hopes for plus-sized profits from obesity drug
1801.HK
- Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
-
Akeso marks profit milestone with swift rights issue
9926.HK
Discover hidden China stock gems in our weekly newsletter